 |
|
COMMENTS AND OPINIONS
HEALTH CARE REFORM
Pharmacists Are Key to Enhancing Benefit Risk for Medicines
Anjan K. Banerjee, DM, MSc, MBA
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The timely article by Murray et al1 prompts me to write. We have produced nearly 30 risk minimization plans to permit the safer use of medicines by patients and to enhance the benefit to risk ratio.2 A key part of such plans, which are now enshrined in the United States under the Food and Drug Administration Amendments Act of 2007 (Pub L No. 110-85), within Risk Evaluation and Mitigation Strategies (REMS) and Risk Minimisation Action Plans, and also the Risk Management Plan of the European Medical Evaluation Agency (EMEA) in the European Union, are measures to minimize the effect of any identified and potential risks.
We have appreciated for some time that many of the most effective risk minimization measures for new medicines are centered around the activities of the pharmacist and the relevant interface with both patients and prescribers.3 Relevant tools can relate . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Effect of a Pharmacist on Adverse Drug Events and Medication Errors in Outpatients With Cardiovascular Disease
Michael D. Murray, Mary E. Ritchey, Jingwei Wu, and Wanzhu Tu
Arch Intern Med. 2009;169(8):757-763.
ABSTRACT
| FULL TEXT
RELATED LETTER
Pharmacists Are Key to Enhancing Benefit Risk for Medicines—Reply
Michael D. Murray
Arch Intern Med. 2009;169(18):1723-1724.
EXTRACT
| FULL TEXT
|
